Drug Trial Radar · NCT05476770
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Last checked: Nov 20, 2026Latest source record: Dec 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
54
Planned (sponsor's estimate)
Start
Nov 11, 2022
Primary completion
Nov 11, 2025
Study completion Nov 11, 2027
Sponsor
- Lead sponsor
- Therapeutic Advances in Childhood Leukemia ConsortiumAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patients with relapsed/refractory hematologic malignancies. The mechanism by which tagraxofusp kills cells is distinct from that of conventional chemotherapy. Tagraxofusp directly targets CD123 that is present on tumor cells, but is expressed at lower or levels or absent on normal hematopoietic stem cells. Tagraxofusp also utilizes a payload that is not cell cycle dependent, making it effective against both highly proliferative tumor cells and also quiescent tumor cells. The rationale for clinical development of tagraxofusp for pediatric patients with hematologic malignancies is based on the ubiquitous and high expression of CD123 on many of these diseases, as well as the highly potent preclinical activity and robust clinical responsiveness in adults observed to date. This trial includes two parts: a monotherapy phase and a combination chemotherapy phase. This design will provide further monotherapy safety data and confirm the FDA approved pediatric dose, as well as provide safety data when combined with chemotherapy. The goal of this study is to improve survival rates in children and young adults with relapsed hematological malignancies, determine the recommended phase 2 dose (RP2D) of tagraxofusp given alone and in combination with chemotherapy, as well as to describe the toxicities, pharmacokinetics, and pharmacodynamic properties of tagraxofusp in pediatric patients. About 54 children and young adults will participate in this study. Patients with Down syndrome will be included in part 1 of the study.
Conditions
- Hematologic Malignancy
- AML
- ALL
- BPDCN
- MDS
- Lymphoblastic Lymphoma
- Lymphoma, B-Cell
- Lymphoma, T-Cell
- Hodgkin Lymphoma
- Mixed Phenotype Acute Leukemia
- Acute Undifferentiated Leukemia
Interventions
TagraxofuspDrug
Dose will be assigned at study entry. Give IV over 15 minutes.
FludarabineDrug
30 mg/m\^2 will be given IV over 30 minutes on days 1-5. Infusion will start 30 minutes after start of tagraxofusp on days 4 and 5.
CytarabineDrug
2000 mg/m2 intravenously will be given daily over 1-3 hours for 5 days on days 1 through 5. Infusion will begin 4 hours after start of fludarabine. Because of an increased risk of neurotoxicity, it is recommended that IT cytarabine be separated from high dose IV cytarabine administration by at least 24 hours on C1D1.
DexamethasoneDrug
* 20 mg/m2/day divided BID (max 40 mg/day) given orally on days 1 through 5 and 15 through 19. The two doses should be separated by at least 8 hours. * Any oral formulation of dexamethasone is acceptable. * IV may be given if oral formulation is not tolerated
VincristineDrug
* 1.5 mg/m2 (maximum dose 2 mg) given intravenously as an IV push over 1-5 minutes or infusion via minibag as per institutional policy on days 1, 8, 15, and 22. * Infusion will start 30 minutes after start of tagraxofusp on day 8.
AzacitidineDrug
* 75 mg/m2 subcutaneously or intravenously will be given daily over 15 minutes for 5 days on days 1 through 5. * Azacitidine will be given 30-60 minutes before beginning the tagraxofusp infusion.
MethotrexateDrug
Give intrathecally: * 8 mg for patients age 1-1.99 * 10 mg for patients age 2-2.99 * 12 mg for patients 3-8.99 years of age * 15 mg for patients ≥9 years of age
Cytarabine ITDrug
Give intrathecally: * 30 mg for patients age 1-1.99 * 50 mg for patients age 2-2.99 * 70 mg for patients ≥3 years of age If given as part of Triple IT Therapy: AML Patients: Age 1-1.99 - 24 mg Age 2-2.99 - 30 mg Age ≥3 years of age - 36 mg AML Patients: Age 1-1.99 - 16 mg Age 2-2.99 - 20 mg Age 3-8.99 - 24 mg Age ≥9 years of age - 30 mg
HydrocortisoneDrug
Given intrathecally. AML Patients: Age 1-1.99 - 16 mg Age 2-2.99 - 20 mg Age ≥3 years of age - 24 mg AML Patients: Age 1-1.99 - 8 mg Age 2-2.99 - 10 mg Age 3-8.99 - 12 mg Age ≥9 years of age - 15 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of dose limiting toxicity (DLT) during cycle 1 of therapyTime frame: At the end of Cycle 1 (21 days for Part 1, and 28 days for Part 2)
Locations
31 sites in 2 countries. Site status is shown where the registry gives one.
Children's Hospital Los Angeles
Los Angeles, California · Recruiting
Children's Hospital Orange County
Orange, California · Not yet recruiting
UCSF School of Medicine
San Francisco, California · Recruiting
Children's Hospital Colorado
Denver, Colorado · Recruiting
Children's National Medical Center
Washington D.C., District of Columbia · Recruiting
University of Miami
Miami, Florida · Not yet recruiting
Children's Healthcare of Atlanta, Emory University
Atlanta, Georgia · Not yet recruiting
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois · Recruiting
Riley Hospital for Children
Indianapolis, Indiana · Recruiting
Johns Hopkins University
Baltimore, Maryland · Not yet recruiting
National Cancer Institute, Pediatric Oncology Branch
Bethesda, Maryland · Not yet recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Not yet recruiting
C.S. Mott Children's Hospital
Ann Arbor, Michigan · Recruiting
Children's Hospital and Clinics of Minnesota
Minneapolis, Minnesota · Not yet recruiting
Children's Hospital New York-Presbyterian
New York, New York · Not yet recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Carolina-Levine Children's Hospital
Charlotte, North Carolina · Not yet recruiting
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio · Recruiting
Rainbow Babies
Cleveland, Ohio · Not yet recruiting
Nationwide Children's Hospital
Columbus, Ohio · Not yet recruiting
Oregon Health & Science University
Portland, Oregon · Not yet recruiting
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania · Not yet recruiting
St. Jude Children's Research Hospital
Memphis, Tennessee · Not yet recruiting
University of Texas, Southwestern
Dallas, Texas · Recruiting
Cook Children's Hospital
Fort Worth, Texas · Recruiting
Texas Children's Hospital/Baylor College of Medicine
Houston, Texas · Recruiting
Primary Children's Hospital
Salt Lake City, Utah · Recruiting
Seattle Children's Hospital
Seattle, Washington · Not yet recruiting
Children's Hospital of Wisconsin
Milwaukee, Wisconsin · Recruiting
Sydney Children's Hospital
Sydney, Australia · Not yet recruiting
Children's Hospital at Westmead
Westmead, New South Wales, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.